StockNews.com began coverage on shares of Syros Pharmaceuticals ( NASDAQ:SYRS – Free Report ) in a report released on Thursday morning. The brokerage issued a hold rating on the stock. A number of other equities analysts have also recently weighed in on the company. HC Wainwright reaffirmed a buy rating and issued a $15.00 price target on shares of Syros Pharmaceuticals in a report on Wednesday, August 9th. Piper Sandler reduced their price target on Syros Pharmaceuticals from $11.00 to $7.

https://www.dailypolitical.com/2023/10/08/syros-pharmaceuticals-nasdaqsyrs-earns-hold-rating-from-analysts-at-stocknews-com.html

#dailypolitical